A global science superpower: the future of medicines valuation
The current pandemic has acted as an important reminder that we need to have the most effective policies in place to support the discovery and development of new treatments, medicines and vaccines. A thriving life sciences ecosystem in the UK today has enabled the UK to show global leadership, through world leading studies on the vaccines and treatments necessary to combat COVID-19.
New treatments can deliver both health and wealth benefits for the country, and the Government has stated its ambition to accelerate patients’ access to the most effective medicines whilst ensuring best value for the NHS. The National Institute for Health and Care Excellence plays a crucial role in this equation by evaluating the cost effectiveness of new treatments, and it is currently undergoing a review of its evaluation methods so that it is able to respond to technological change and innovation to ensure the right access, for the right patients, at the right value.
This event focused on the opportunities and challenges that lie ahead in medicines valuation, as well as how to ensure that the most effective drugs reach patients. This event was held in partnership with the Association for the British Pharmaceutical Industry.
- Lord Bethell of Romford, Parliamentary Under Secretary of State, Department of Health and Social Care
- Professor Gillian Leng CBE, Chief Executive, National Institute for Health and Care Excellence (NICE)
- Samantha Benham-Hermetz, Director of Policy and Public Affairs, Alzheimer’s Research UK
- Dr Richard Torbett, Chief Executive, Association of the British Pharmaceutical Industry
- Eleonora Harwich, Director of Research, Reform (Chair)